With this enhancement in the CureMD application, users navigate seamlessly to the Tumor Assessment tab from various other tabs within the Research section of a patient’s clinical details. This facilitates efficient tumor assessment management and supports compliance in clinical trials.
With this enhancement in the CureMD application, clinicians are guided through an NCCN Concordance Check when ordering custom regimens, ensuring compliance with NCCN guidelines. The system offers a selection of verified NCCN regimens for comparison, helping to streamline the process
With this enhancement in the CureMD application, users can document a Baseline Timepoint when adding a timepoint for the first time in Tumor Assessment, following RECIST guidelines. This includes fields for radiology details, target and non-target lesions, and more, providing comprehensive data entry for baseline assessments.
With this enhancement in the CureMD application, a "Tumor Assessment" button has been added to the Patient's Clinical side navbar, enabling quick access to the Tumor Assessment tab. Users with the appropriate permissions can easily navigate to this section for streamlined workflow.
With this enhancement in the CureMD application, administrators can control user access to the Tumor Assessment tab by managing specific permissions. These permissions include options to view, add, edit, or delete tumor assessments, providing greater control over user roles.
With this enhancement in the CureMD application, users can view an electronic signature on the Chemotherapy Administration Report, ensuring clear representation of the signer. Practices can configure the signature display based on preferences, improving documentation accuracy and accountability.
With this enhancement in the CureMD application, users can select and print specific lab results on the Chemotherapy Admin Form for more personalized reporting. The system saves these preferences, allowing streamlined lab result display for each patient.
With this enhancement in the CureMD application, users can see an electronic signature on the Chemotherapy Preauthorization Report after signing it. This ensures clear identification of the signing user, improving accountability in documentation.
Posted On: Oct 29, 2024
Posted On: Oct 29, 2024
Posted On: Oct 29, 2024
Posted On: Oct 29, 2024
Posted On: Oct 29, 2024
Posted On: Oct 29, 2024